Personalized cancer medicine: Arewethere yet?

Oncologist

Volumn 18, Issue 6, 2013, Pages 649-650

  Lawler, Mark ^a   Selby, Peter ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; IPILIMUMAB; VEMURAFENIB;

CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; DRUG COST; DRUG DESIGN; DRUG INDUSTRY; ECONOMIC ASPECT; HUMAN; MELANOMA; NOTE; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS;

EID: 84879467032     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0189     Document Type: Note

References (7)

1. von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs-Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998;4:1079-1086.
2. Doroshow JH, Sleijfer S, Stupp R et al. Cancerclinical trials-Do we need a newalgorithm in the age ofstrat-ified medicine? The Oncologist 2013;18:651-652.
3. Liu ET, Johnston PG. Personalized Medicine: Does the Molecular Suit Fit? The Oncologist 2013; 18:653-654.
4. Eggermont AM, Robert C. Melanoma in 2011: A new paradigm tumor for drug development. Nat Rev Clin Oncol 2012;9:74-76.
5. Druker BJ. Perspectives on the development of imatinib and the future ofcancerresearch. Nat Med 2009;15:1149-1152.
6. O'Hare T, Zabriskie MS, Eiring AM et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012;12:513-526.
7. Kantarjian H et al. Priceofdrugsforchronic myeloid leukemia (CML), reflection ofthe unsustain-ablecancerdrugprices: perspective of CML Experts. Blood 2013 [Epubahead of print].